SLC5A2 and diabetic kidney disease: The renal benefits of classic ACE inhibitor or ARB, as well as newly emerging SGLT2 inhibitor in DKD patients, are all demonstrated by large-scale RCTs and then recommended in authoritative guidelines [23,24,62–64].